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Cholinergic neurons and nicotinic acetylcholine receptors (nAChRs) in the brain participate in diverse
functions: reward, learning and memory, mood, sensory processing, pain, and neuroprotection. Nicotinic
systems also have well-known roles in drug abuse. Here, we review recent insights into nicotinic function,
linking exogenous and endogenous manipulations of nAChRs to alterations in synapses, circuits, and
behavior. We also discuss how these contemporary advances can motivate attempts to exploit nicotinic
systems therapeutically in Parkinson’s disease, cognitive decline, epilepsy, and schizophrenia.Introduction
Europeans first encountered nicotinic actions when Columbus’s
crew sampled tobacco in 1492. After Jean Nicot, the French
ambassador to Portugal, introduced tobacco to Paris, botanists
honored him by naming the plant Nicotiana, and later its active
alkaloid was named nicotine. Claude Bernard (1851) found that
nicotine activates muscle when applied directly but not when
applied to motor nerves; this was eventually explained by the
fact that nicotine and neurally released acetylcholine activate
common receptors. In 2011, we know that cholinergic actions
in the brain govern various processes: cognition (attention and
executive function) (Couey et al., 2007; Levin and Rezvani,
2007; Heath and Picciotto, 2009; Howe et al., 2010), learning
and memory (Gould, 2006; Couey et al., 2007; Levin and
Rezvani, 2007), mood (anxiety, depression) (Picciotto et al.,
2008), reward (addiction, craving) (Tang and Dani, 2009), and
sensory processing (Heath and Picciotto, 2009).
The discoveries of Katz and contemporaries at the nerve-
muscle synapse and autonomic ganglia gave rise to the modern
view that the nicotinic cholinergic synapse is an exquisite
biophysical switch, specialized to function on a time scale
of 1 ms and a distance scale of < 1 mm (Wathey et al., 1979;
Stiles et al., 1996). This picture did not, however, conform well
to the view that acetylcholine functions in the brain as primarily
a slow, more widespread modulatory transmitter, somewhat
analogous to the biogenic amines. Until the mid-1980s, the
‘‘switch’’ versus ‘‘modulator’’ views were generally reconciled
by assuming that nicotinic acetylcholine receptors (nAChRs)
activated the dopaminergic system (thus explaining the feeling
of well-being during smoking), while most cholinergic actions
in the brain occur via muscarinic acetylcholine receptors. This
assumption became untenable when specific nicotine binding,
and cloned neuronal nAChRs, were found in many brain regions
(Marks et al., 1983; Schwartz and Kellar, 1983; Heinemann et al.,
1987). We now realize that acetylcholine liberated from cholin-
ergic nerve terminals often activates both nAChRs and musca-
rinic receptors.
Well-characterized cholinergic projection neurons in the brain
include those of the basal forebrain, the medial habenula, the20 Neuron 70, April 14, 2011 ª2011 Elsevier Inc.striatum, and the vagal nucleus. Terminals of basal forebrain
neurons radiate widely and richly innervate forebrain structures.
The giant cholinergic interneurons of the striatum control
several aspects of basal ganglia function (Cragg, 2006; Witten
et al., 2010). Specificity within the cholinergic system arises in
part through its receptors. Muscarinic and nicotinic classes
comprise five and fifteen subunits, respectively. Nicotinic
receptors are pentamers (Figure 1); brain nicotinic receptors
can exist as heteromeric combinations of a(2-10) and b(2-4)
subunits, and as a7 homopentamers (in muscle-type receptors,
the non-a subunits are b1, g or 3, and d). Each nAChR subtype
exhibits distinct biophysical and pharmacological properties.
Even the precise order and stoichiometry of a and b subunits
in the pentamer imposes differential response profiles. A major
subtype in the brain is a4b2; the (a42b23) stoichiometry exhibits
at least 10-fold-higher sensitivity than (a43b22), so that only
the former has the high sensitivity (HS) that allows activation
at nicotine concentrations in the 0.1–1 mM range, produced
by moderate tobacco use and by the various nicotine replace-
ment therapies. a7 nAChRs also respond to nicotine concentra-
tions roughly an order of magnitude higher than a42b23, and a7
nAChRs have high Ca2+ permeability resembling that of NMDA
receptors.
Most brain HS nAChRs reside on presynaptic terminals,
where they stimulate neurotransmitter release (Gotti et al.,
2006; Albuquerque et al., 2009). Such presynaptic nAChR acti-
vation influences synaptic efficacy and synaptic plasticity
(Mansvelder and McGehee, 2000; Dani et al., 2001), spike-
timing-dependent plasticity (Couey et al., 2007), frequency-
dependent filtering (Exley and Cragg, 2008; Tang and Dani,
2009; Zhang et al., 2009), and overall signal-to-noise ratio in
cortex (Disney et al., 2007). Many studies also reveal the
presence of somatodendritic nAChRs, but there are relatively
few classically defined somatodendritic cholinergic synapses
(Aznavour et al., 2005). The ‘‘volume transmission’’ hypothesis
states that ACh released from presynaptic terminals spreads
to more distant areas, reaching concentrations < 1 mM (Descar-
ries et al., 1997), but that multiple presynaptic impulses produce
enough summed release to activate receptors (Lester, 2004).
Figure 1. Major Characteristics of Some
nAChRs
(A) A diagram of the symmetric or pseudosym-
metric pentameric extracellular binding region,
modeled by the acetylcholine receptor binding
protein AChBP. The eyepoint is the cytosol; the
side chains and transmembrane domains do not
appear. The exemplar agonist (nicotine) is repre-
sented in black; two agonist binding sites form
at the interface between subunits. The open
state of the ion channel is more likely to occur
when agonist molecules bind at both interfaces
than at a single interface. An a subunit (red and
yellow) always participates in the binding inter-
face; the other participants are either a subunits
(in a7 homopentameric nAChRs) or non-a subunits
(in heteropentameric nAChRs such as a4b2*);
(see the table in C). The auxiliary subunit (aux, in
blue) does not participate in an agonist binding
site.
(B) Depiction of a nAChR molecule in the
membrane. The eyepoint is a neighboring nAChR.
The receptor is Unwin’s model for the Torpedo
electric organ muscle-type AChR (Unwin, 2005).
The model depicts the full extracellular region
(mostly b sheets), which strongly resembles the
AChBP structure shown in (A). Ribbons depict the
structural elements, whereas neither backbone
nor side-chain atoms appear. The model includes
the full transmembrane region (mostly a-helical)
and only part of the intracellular domains. The
schematic also imagines a lynx molecule (red)
bound at an a/non-a interface, positioned as in
structures of snake a-toxins bound to AChBP
(Hansen et al., 2005) or to the muscle nAChR
(Dellisanti et al., 2007). Lynx binding, as indepen-
dently proposed in a recent study (Lyukmanova et al., 2011), occurs at the agonist site shown in (A). The lynx molecule, unlike toxins, is tethered to the membrane
by a GPI linkage, here stretched to nearly its full extent and depicted as five hexagons.
(C) Some major nAChR subtypes found in brain. Each column represents the composition of a single pentameric receptor. The table shows our best present
knowledge about the properties of detailed stoichiometries. The colored boxes correspond to the subunits of (A) and (B). The bracket and the nicotine molecules
show the agonist-binding interfaces between individual subunits. Expression of each receptor subtype is wide-spread (WS), or restricted in the case of a6*
nAChRs, confined largely to dopaminergic neurons (DA), noradrenergic neurons (NA), or retinal ganglion cells (RGC).
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density of acetylcholinesterase (which can hydrolyze ACh at
a rate of one per 100 ms!) might vitiate the volume transmission
mechanism. In the interpeduncular nucleus, the acetylcholines-
terase density is sufficiently low to rationalize long-awaited,
recent evidence that 20–50 Hz presynaptic stimulation eventu-
ally generates a postsynaptic response via volume transmission
(Ren et al., 2011). As we will see below, the mystery of somato-
dendritic nAChRs can also be resolved by the sensitivity of a7
nAChRs to constant levels of another agonist, choline.
Although researchers have located the cholinergic neurons
and the nicotinic receptors, the problem remains: how can
changes in biophysical switches lead to widespread modula-
tion? A series of explanations arise, because nicotinic systems
are tightly balanced through a multilayered hierarchy of control
mechanisms. Acetylcholinesterase efficiently hydrolyzes acetyl-
choline, both turning off cholinergic signaling and also reducing
the likelihood of receptor desensitization. In addition, changes in
subunit composition and stoichiometry can influence receptor
desensitization, ligand affinity profiles, and conductance. Muta-
tions in nicotinic receptor subunits are linked to human disease,
a4 and b2 in some epilepsies, a7 in schizophrenia, and a5 in
nicotine addiction; and each mutation ultimately manifests itself
as an imbalance in the properties of neuronal circuits. Hyperac-tivating mutations in nAChR subunits have revealed the exis-
tence of previously underappreciated cholinergic mechanisms
(Fonck et al., 2005; Drenan et al., 2008). Furthermore, posttrans-
lational mechanisms such as upregulation can play a part in
modifying the response properties of nAChRs and may underlie
susceptibility toward nicotine dependence. Finally, nAChRs
exist in complexes in the brain; interacting proteins engage in
complexes with nAChRs and aid in the assembly and trafficking
of nAChR to the plasma membrane; examples are RIC-3 (Lans-
dell et al., 2005), 14-3-3 proteins (Jeanclos et al., 2001), neurex-
ins (Cheng et al., 2009), and VILIP-1 (Lin et al., 2002).
The challenge of explaining the modulation of behavior in
terms of the microscopic properties of all-or-none synapses
occupies much of neuroscience; but one expects studies on
nicotinic systems to lead the way, if only because of their vener-
ability. Within the control hierarchy, especially sensitive points of
regulation can have important sequelae. This review discusses
three emerging hypotheses about ways that the nicotinic system
can be modulated. First is the role played by lynx modulators as
molecular brakes over the cholinergic system in stabilizing neural
plasticity and circuitry. A second example is a critical time in
neurodevelopment that controls the maturation of inhibition;
misregulation of a7 nAChR function may lead to increased
risk of schizophrenia. Lastly, we discuss how chronic nicotineNeuron 70, April 14, 2011 ª2011 Elsevier Inc. 21
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also to two inadvertent therapeutic effects.
Neuromodulation through Lynx Protein Modulators
of nAChR Function
Maintaining the levels and function of nAChRs during develop-
ment and in adulthood is critical for proper circuit function. An
inverted U-shape characterizes an organism’s response to
cholinergic activators. On the extremes of this range, underacti-
vation is associated with lower cognitive performance and
dementias (Hasselmo and Sarter, 2011), whereas overactivation
may be linked to epilepsy (Bertrand et al., 2002) and, in even
more extreme cases, to neurodegeneration (Schwarz et al.,
2006). Apparently, tight control over cholinergic systems,
operating at several levels, can counteract such imbalances at
both extremes. Proteins that engage nAChRs within stable
complexes, such as lynx family members, provide a homeostatic
influence over nicotinic receptor systems. Through functionally
driven regulation of lynx expression, the inhibition exerted over
the system can be released or enhanced selectively within
neuronal circuits.
The Lynx Family Acts as Nicotinic Receptor Modulators
The lynx genes belong to the ly-6/PLAUR superfamily, which
shares a marked structural similarity with elapid snake venom
proteins such as a-bungarotoxin; all have a characteristic
three-looped motif. These a-neurotoxins are secreted proteins
with sub-nM affinity for nAChRs (Tsetlin et al., 2009) and other
receptors (Auer et al., 2010). a-neurotoxins interact on the extra-
cellular face of the nAChR near ligand binding sites (Figure 1B),
in contrast to most other nAChR-interacting proteins, which bind
to the intracellular loops. Extrapolating from these interactions,
the structurally similar lynx proteins may bind at such sites as
well (Lyukmanova et al., 2011). Five interfaces occur in each
nAChR pentamer (Figure 1); we do not yet know which, if any,
interfaces form the binding sites for various lynx paralogs
(Hansen and Taylor, 2007). Most previous studies of lynx have
emphasized interactions at the plasma membrane. As GPI-
anchored proteins can bind to transmembrane receptors intra-
cellularly, the interactions of lynx with nAChRs could potentially
alter receptor trafficking, stoichiometry, and surface number
(Lester et al., 2009).
The high level of conservation with toxins implies that lynx
genes are prototoxins—evolutionary antecedents to a-neuro-
toxins (Miwa et al., 1999; Chimienti et al., 2003; Dessaud et al.,
2006; Arredondo et al., 2007; Hruska et al., 2009). The lynx family
occurs in other species, including C. elegans (Chou et al., 2001)
and Drosophila (Wu et al., 2010)—and in nonvenomous snakes,
where it is distinct from the neurotoxin genes. We note that, in
several cases, snake toxins employ functional mimicry of
proteins in normal physiological processes. Often, virulent gene
variants distort endogenouspathways at sensitive or rate-limiting
steps. Therefore, the evolutionary relationship between lynx
modulators and the a-neurotoxins agrees with the view that
lynx modulators govern critical control points in the pathway of
nicotinic receptor signaling.
Lynx1, the first discovered member of this family expressed in
the brain (Miwa et al., 1999), has an overall inhibitory effect on
nAChR function. In an a4b2* nAChR-expressing cell, coexpres-22 Neuron 70, April 14, 2011 ª2011 Elsevier Inc.sion of lynx1 results in reduced agonist sensitivity, accelerated
onset of desensitization, and slower recovery from desensitiza-
tion (Iban˜ez-Tallon et al., 2002). Each lynx paralog has a relative
binding specificity and modulatory capability on a4b2 (Miwa
et al., 1999; Iban˜ez-Tallon et al., 2002; Levitin et al., 2008), a3
(Arredondo et al., 2006), and a7 (Chimienti et al., 2003; Levitin
et al., 2008; Hruska et al., 2009) nAChR subtypes; some interac-
tions actually enhance nicotinic responses (Chimienti et al.,
2003; Levitin et al., 2008), or their Ca2+ components (Darvas
et al., 2009). The actions of lynx family proteins manifest them-
selves at both circuit (Hruska et al., 2009) and network levels
(Pfeffer et al., 2009) on nicotinic systems. The blunting effect of
lynx proteins could be responsible for the paucity of synaptically
driven nicotinic responses recorded in brain tissue despite the
rich cholinergic innervation, as well as the different response
properties in brain tissue as compared with heterologous
expression systems (Quick and Lester, 2002).
Lynx Acts as a Molecular Brake on Cholinergic-
Dependent Plasticity
Removal of the molecular brake provided by lynx proteins can
lead to nicotinic receptor hypersensitivity—larger direct nicotinic
responses, slowed desensitization kinetics (Miwa et al., 2006),
and enhanced sensitivity of the EPSC frequency in the cortex
to nicotine (Tekinay et al., 2009). As a consequence of nAChR
hypersensitivity, lynx1 knockout mice display increased levels
of Ca2+ in neurons, enhancements in synaptic efficacy, and
improved learning and memory functions (Miwa et al., 2006;
Darvas et al., 2009; Tekinay et al., 2009). Studies on such hyper-
active nicotinic receptors can reveal cholinergic-dependent
processes with increased clarity. For instance, adult lynx1KO
mice display heightened ocular dominance plasticity after the
normal close of the critical period (Morishita et al., 2010). While
the role of the cholinergic system during visual processing
(Disney et al., 2007) and development has been appreciated
(Bear and Singer, 1986), it has been a mystery why the critical
period closes in late postnatal development and remains closed
despite heavy cholinergic innervation of the visual system. These
findings indicate that suppression of the cholinergic system by
lynx proteins stabilizes neural circuitry. Indeed, cholinergic
enhancement (via cholinesterase inhibition) reopens the critical
period for visual acuity in adult wild-type mice (Morishita et al.,
2010), indicating that cellular mechanisms for robust plasticity
are maintained in adulthood through the cholinergic system
but are suppressed by the action of lynx.
Top-Down Control over the Cholinergic System through
Lynx: What Regulates the Regulator?
Abolishing receptor function through null mutations or pharma-
cological blockers of nAChRs abolished some of the gain-of-
function phenotypes in lynx mouse models, indicating that
nAChRs are necessary for the expression of lynx perturbations
(Miwa et al., 2006). This indicates that lynx proteins exist, genet-
ically, as upstreammodulators of nicotinic receptor function and
cholinergic signaling and can exert control over cholinergic-
dependent processes. Because excess activation of nAChRs
damages neuronal health and brain function, organisms have
a clear need to restrict the degree of nAChR activation. Yet
specific enhancement of cholinergic activity in functional circuits
would benefit many processes, as described above. Therefore,
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cholinergic system to shift in response to environmental changes
would be critical. Partial, transient, or local reductions in lynx
function may produce an optimal balance; moderate cholinergic
signaling would enhance synaptic plasticity, yet still protect
against hyperactivation that could make neurons susceptible
to excitotoxic damage. What, then, regulates the regulator?
Evidence thus far indicates that the lynx family is regulated in
response to relatively strong perturbations: downregulation in
NKCC1 knockout mice (Pfeffer et al., 2009), in adenylyl cyclase
mutantmice (Wieczorek et al., 2010), and by a7 nAChR blockade
(Hruska et al., 2009), whereas it is upregulated at the close of the
critical period in the visual cortex, and by nicotine in the lung (Se-
khon et al., 2005). Through functionally driven regulation of lynx
expression, cholinergic systems have the ability to exert top-
down influences on circuits underlying relevant behavior via
coordinated regulation of nicotinic receptors subsets. While
genetic linkages of lynx family members to neurological disor-
ders have not been found, evidence for cholinergic dysregulation
has been linked to a lynx family member expressed in nonneuro-
nal tissues and involved in human disease (Chimienti et al.,
2003), and as such, alterations in lynx dosage may be useful in
ameliorating cognitive decline associated with neuropsychiatric
disorders.
Lynx Modulators and the Neurodevelopmental Program
The synaptic pruning of neuronal circuits takes place late in the
developing brain, after a period of early sculpting of neuronal
number through programmed cell death. Nicotinic receptor
systemshavebeen implicated at both these stages and evidence
suggests an involvement with lynx prototoxins as well. For
instance, early expression of lynx1 family member, PSCA,
prevents programmed cell death of parasympathetic neurons
(Hruska et al., 2009). Neuronal maturation and loss of synaptic
lability appear tobe correlatedwith the onset of lynx1 expression.
In themajority of cases, circuit stabilitywould provide anadaptive
advantage once sculpting of circuitry has been influenced by
the patterned activity of experience. Temporal coherence of
information is critical for creating a stable internal representation
of our environment and provides the background for salient
information to reach our attention. But what happens in cases
when that program goes awry? Lynx1 is downregulated in
NKCC1 KO mice (Pfeffer et al., 2009), a strain that has a delayed
developmental program of GABAergic neurons, diminished
inhibition, and less spontaneous network activity. The neurode-
velopmental program depends in part on a7 signaling (Liu et al.,
2006). Lynx1 upregulation during a critical neurodevelopmental
period, the switch in the sign of GABAergic signaling, and
coexpression of lynx with GABAergic subsets all indicate a
possible role of lynx mediating the timing of such developmental
transitions. Nicotinic receptor control over GABAergic neuronal
development and mature activity may represent a point of
convergence for diseases such as schizophrenia (see next
section), some amblyopias (Bavelier et al., 2010), and some
epilepsies (Klaassen et al., 2006), which distort the excitatory-
inhibitory balance in general and implicate GABAergic signaling
defects in particular. In such cases, interventions through lynx
could be useful for reestablishing the robust plasticity of youth
exhibited prior to the close of the critical period, for instance incases of amblyopia or brain repair in stroke. Further, manipula-
tions of lynx activity could help to restore proper inhibitory-excit-
atory imbalance. Developmental changes in nAChR functions
may play a role in nicotine addiction, as a central question in
tobacco control is young adult smokers’ marked sensitivity to
developing nicotine dependence (DSM-V Nicotine Workgroup,
2010; DiFranza et al., 2000; Difranza, 2010). Molecules, such as
lynx, which have direct contacts with nAChRs are promising
candidates for the control of such phenomena and sensitive
periods.
An Emerging Role for a7 nAChRs in Schizophrenia:
Pharmacotherapeutic and Developmental Perspectives
Individuals with schizophrenia have a number of elementary
psychophysiological abnormalities in filtering sensory stimuli
that have been hypothesized to underlie their characteristic
hallucinations and delusions (Venables, 1967). Their hallucinated
voices and paranoid suspicions sometimes can be triggered by
background noises in the environment that most other people
can ignore. For example, a common hallucination in schizo-
phrenia is a voice from the television, perhaps combined with
the paranoid delusion that the television is commanding certain
actions. The breakthrough of background noises into hallucina-
tions and delusions can be considered a nonspecific manifesta-
tion of disorganized thinking, but increasingly it has been
conceptualized as more specific evidence for failure in elemen-
tary inhibitory processes that the brain uses to regulate the
amount of sensory stimuli that it processes. In many persons
with schizophrenia, cerebral evoked potential recording shows
diminished inhibition of the response to repeated stimuli (Adler
et al., 1982) (Figure 2A), and animal models of this phenomenon
point to a defect in hippocampal inhibition. Recent studies
provide evidence both that nicotinic signaling partially underlies
these schizophrenia-related inhibitory defects and that nicotinic
drugs have possible therapeutic roles.
Cerebral a7 nAChRs in Cortex and Thalamus
The hippocampus responds to repeated stimuli with rapid habit-
uation, which is dependent upon cholinergic input from the
medial septal nucleus, an input that is driven by the brainstem
reticular formation. a7 nAChRs on inhibitory interneurons
throughout the hippocampus and presynaptic a7 nAChRs on
mossy fiber terminals in the dentate gyrus participate in the
control of sensory response in the hippocampus (Gray et al.,
1996; Alkondon et al., 1999). Nicotinic activation of inhibitory
interneurons increases their activity and activates nitric oxide
synthetase. The neurons release additional GABA, activating
presynaptic GABAB receptors on the excitatory inputs to pyra-
midal neurons, which diminish the release of glutamate onto
the pyramidal neurons (Figure 2). The result is diminished pyra-
midal neuron response to repeated sensory stimuli. Thus, the
brainstem can regulate hippocampal response in the presence
of high sensory input. Although a7 nAChRs have both presyn-
aptic and postsynaptic expression (Frazier et al., 1998), their
postsynaptic expression in humans is especially marked on
inhibitory neurons of the hippocampus (Alkondon et al., 2000).
Rodents have similar expression in the hippocampus, but
primates have much more expression in the interneurons of
the nucleus reticularis thalamis; the selective advantage of thisNeuron 70, April 14, 2011 ª2011 Elsevier Inc. 23
Figure 2. Aspects of nAChR Subtypes on Circuit Function
(A) Sensory inhibition deficits in schizophrenia. Cerebral evoked P50 potentials to repeated sounds (S1, S2) are inhibited in a normal (control, upper trace) but not
in a schizophrenia patient (SZ, bottom trace).
(B) Differential localization of nAChRs subtypes on neurons in the prefrontal cortex. Green cells are excitatory pyramidal neurons (P) and blue cells are inhibitory
interneurons. FS, fast-spiking interneurons; LTS, low threshold spiking; RSNP, regular spiking nonpyramidal neuron. Adapted with permission from Poorthuis
et al. (2009).
(C) Development of a7nAChRs in hippocampus. In the fetal brain before cholinergic innervation occurs (left), a7 nAChRs are somatodendritic and presynaptic on
both GABAergic and glutamatergic neurons. In adults (right), a7 nAChR expression is generally reduced. Receptors are still expressed on GABAergic and
glutamatergic presynaptic terminals, but only GABAergic neurons express somatodendritic a7 nAChRs (figure courtesy of William Proctor).
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input to the cerebral cortex.
Three lines of evidence support the possibility that the failure
of sensory inhibition in schizophrenia results from decreased
expression of a7 nAChRs. First, postmortem studies of the
hippocampus and thalamus show diminished labeling of puta-
tive inhibitory neurons by a-bungarotoxin, an antagonist of a7
nAChRs (Court et al., 1999). Second, the defect in inhibition is
linked to the chromosome 15q14 locus of CHRNA7, the gene
for the a7 nAChR subunit. Polymorphisms in the a7 50 promoter
and in a nearby partial duplication of the gene, FAM7A, are
associated with both schizophrenia and the defect in inhibition
(Leonard et al., 2002). It should, however, be noted that many
genes have been associated with schizophrenia and there is
no definitive model of its genetic transmission. Yet some of
the other genes identified, such as NRG1, are involved in the
assembly of a7 nAChRs, further supporting a potential link
between a7 nAChRs and schizophrenia (Mathew et al., 2007).
Third, persons with schizophrenia have the greatest rate and
intensity of cigarette smoking of any identifiable subgroup in
the population. Over 80% smoke, most of them multiple packs
per day. Per cigarette they extract more nicotine than other24 Neuron 70, April 14, 2011 ª2011 Elsevier Inc.smokers with comparable cigarette consumption by inhaling
more deeply and holding the smoke in their lungs. Cigarette
smoking transiently improves their sensory inhibition. While it is
not yet possible to know precisely how well a7 nAChRs are acti-
vated by smoked nicotine, one can reasonably hypothesize that
the patients’ higher dose of nicotine activates a7 nAChRs (Adler
et al., 1993; Papke and Thinschmidt, 1998; Royal College of
Physicians, 2007). Inhibition of the evoked response to auditory
stimuli is significantly increased after patients smoke, an effect
that is blocked by antagonists of a7 nAChRs in animal models
(Luntz-Leybman et al., 1992). In schizophrenics, long-term
cellular and molecular sequelae of this heavy exposure to nico-
tine may transcend chaperone-dependent upregulation (see
next section) and also arise from the high Ca2+ permeability of
nAChRs, especially of a7 nAChRs (Brunzell et al., 2003). Ca2+
activated signal transduction pathways reshape synaptic trans-
mission and neural circuits, in some cases leading to gene acti-
vation (Kauer and Malenka, 2007).
If part of the genetic risk for schizophrenia involves variants in
genes involved in formation of a7 nAChRs, then that risk has
developmental significance as well. Schizophrenia generally
appears in early adulthood, but long before the eruption of
Neuron
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psychophysiological evidence for abnormalities in children with
schizophrenic parents (which increase their risk of the illness).
Such is the case with sensory inhibitory deficits. These are
apparent at birth in some neonateswith a parent who has schizo-
phrenia (Hunter et al., 2010). Mothers who smoke during preg-
nancy are also likely to have a neonate with a sensory inhibitory
deficit. Chronic exposure to nicotine would be expected to
desensitize a7 nAChRs and thus lead to their dysfunction during
development. Immature neurons that express a7 nAChRs are
more likely to be injured by neonatal nicotine, whereas the
expression of heteromeric a4b2* nAChRs by more mature
neurons may contribute to increased survival (Huang et al.,
2007).
Like other nicotinic receptors, a7 nAChRs are thus potential
targets for new therapeutic interventions for neural diseases
such as schizophrenia. Several clinical trials involving schizo-
phrenics have utilized more specific agonists for a7 nAChRs.
3-(2,4 dimethoxy)-benzylidene-anabaseine, derived from an
alkaloid produced by nemertine worms, is a partial agonist at
a7 nAChRs. It improves sensory inhibition in schizophrenics
and also moderately improves their neuropsychological deficits
in attention (Olincy et al., 2006). Clinical ratings of their negative
symptoms, particularly anhedonia (absence of a sense of plea-
sure) and alogia (poverty of content in their speech), also improve
during treatment. The atypical antipsychotic clozapine uniquely
reduces smoking in schizophrenia, possibly because it releases
acetylcholine in the hippocampus, activating a7 nAChRs
(George et al., 1995). These clinical observations indicate that
the patients’ cognitive deficits are more amenable to treatment
thanmany previously believed and their heavy cigarette smoking
suggests that prescribed neurobiological treatment does not yet
adequately address the brain pathophysiology of schizophrenia.
a7 nAChRs and the Development of Inhibitory
Neuronal Circuitry
Like many genes expressed in the brain, the expression of a7
nAChRs is maximal during development. a7 nAChRs first appear
on neuroblasts as soon as they differentiate from the neuroepi-
thelium, and the peak expression occurs just after birth in
rodents (Adams, 2003). In the third trimester, the expression of
a7nAChRs in the hippocampus is greater than three times the
level in adults. The postsynaptic expression, confined to inter-
neurons in adults, is prominent on fetal pyramidal neurons as
well (Figure 2C). One important role for a7 nAChRs, in conjunc-
tion with a3-containing nAChRs, is the induction of the KCC2
chloride transporter in pyramidal neurons (Liu et al., 2006). This
transporter lowers the internal Cl concentration of the neuron
and changes GABA from a depolarizing to a hyperpolarizing or
inhibitory neurotransmitter. A specific role of a7 nAChRs was
demonstrated by failure of the induction of KCC2 by treatment
with a7 nAChR antagonists and in a7 KO mice (Zhang and
Berg, 2007). At the time of birth, a7 nAChRs are involved in the
transformation of glutamate neurotransmission from primarily
NMDA-type receptors to kainate-aspartate receptors. a7
nAChRs remain embedded in the glutamate receptor-containing
postsynaptic density.
Cholinergic innervation of the hippocampus occurs near the
time of birth; therefore, the endogenous ligand for fetal a7nAChRs cannot be synaptically released acetylcholine (Derring-
ton and Borroni, 1990). A possible candidate is choline, which, in
addition to its other development roles, activates a7 nAChRs at
levels several fold higher than acetylcholine. Choline levels in
human neonatal cord blood (35 mM) are three times higher
than those in adult blood (Zeisel et al., 1980). These levels are
sufficient to selectively downregulate a7 nAChRs on hippo-
campal neurons in tissue culture, perhaps reflecting a chronic
low level of receptor stimulation (Alkondon et al., 1997; Uteshev
et al., 2003). Brief choline treatment during gestation is associ-
ated with increased excitability and dendritic development in
hippocampal pyramidal neurons (Li et al., 2004).
Choline is an essential dietary nutrient. Normally humans have
adequate choline, but during pregnancy many women are
thought to be deficient because the fetus makes large demands
for use in the synthesis of cell membranes (Meck and Williams,
2003). In addition to poor maternal diet, choline deficiency for
the fetus can occur because of maternal stress, which leads
the mother to sequester choline in her own liver. Variants in the
gene for phosphatidylethanolamine methyl transferase, which
synthesizes phosphatidylcholine and thus provides a source of
choline, are also associated with choline deficiency and with
schizophrenia. Experiments in animal models suggest that
choline supplementation during gestation and early postnatal
development may produce a reversal of sensory inhibitory defi-
cits that lasts through adulthood (Li et al., 2004). Clinical trials
are currently in progress.
In addition to genetic risk, exposure to nicotine, and dietary
deficiency, maternal infection is a risk factor for schizophrenia
(Patterson, 2007). In some cases the infectious agent enters
the fetus, but in most cases, like influenza, it remains in the
mother’s respiratory tract. It is the deleterious effect of her cyto-
kine response to the infection on the placenta that appears to be
pathogenic. a7 nAChRs are involved in the macrophage and
placental cytokine response, which may be an additional role
for genetic variants in these receptors in the pathogenesis of
schizophrenia (Wang et al., 2003).
In short, schizophrenia remains a challenging and mysterious
disease. Yet the perinatal development of a7 nAChRs, the role of
the endogenous agonist choline on a7 nAChRs, and the conse-
quences formaturation of inhibitory circuits provide both a partial
pathophysiological role and a promising avenue for therapy of
schizophrenia.
Effects of Chronic Nicotine: Role of Upregulation
‘‘It’s easy to quit smoking,’’ Mark Twain reportedly said. ‘‘I’ve
done it a hundred times.’’ Nicotine dependence may be the
most complex of the addictions, perhaps both because HS
nAChRs occur in so many brain areas and because unlike acute
opioid administration, nicotine allows a user to remain active and
productive.
Maintained or repeated intake of nicotine occurs during
tobacco smoking or chewing and during the use of snus,
lozenges, gums, or patches. The peak and maintained nicotine
concentrations during such intake are lower than those presum-
ably associated with schizophrenics’ smoking, and they
primarily activate HS nAChRs (Matta et al., 2007; Royal College
of Physicians, 2007). In contrast to nicotine addiction, andNeuron 70, April 14, 2011 ª2011 Elsevier Inc. 25
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produces inadvertent therapeutic effects in at least two other
conditions, Parkinson’s disease and a specific form of epilepsy.
This section discusses the status of the unifying hypothesis
that these three effects of chronic nicotine exposure are
explained by a common molecular and cellular phenomenon. In
brief, the interaction between chronic nicotine and HS nAChRs,
especially a4b2, appears to cause selective upregulation of these
nAChRs via posttranslational mechanisms.
A Pathological Effect: Brain Mechanisms
of Nicotine Dependence
Nicotine-dependent people value the effects produced by the
smoking-induced nicotine bolus that activates and then desensi-
tizes nAChRs; but longer-term exposure is essential for nicotine
dependence (Markou, 2008; Kalivas, 2009; Koob and Volkow,
2010). Themeaning of ‘‘longer term’’ depends on one’s definition
of nicotine dependence, a lively topic in itself (DSM-V Nicotine
Workgroup, 2010; DiFranza et al., 2000; Difranza, 2010); the
time required may be as brief as several days.
Some people use tobacco repeatedly because it provides
a feeling of well-being, which probably begins when nicotine rea-
ches midbrain nAChRs (Matta et al., 2007; Royal College of
Physicians, 2007). Nicotine both activates and desensitizes
nAChRs in midbrain dopaminergic neurons (Brodie, 1991; Pido-
plichko et al., 1997), and the pleasurable effects associated with
nicotine intake occur in large part via the mesolimbic dopami-
nergic reward system (Corrigall et al., 1992; Koob and Volkow,
2010). Recent studies also show important contributions from
insular cortex (Naqvi et al., 2007). The nAChR-rich medial
habenula may actually participate in aversive effects of nicotine
(Fowler et al., 2011), which apparently underlie moderate
smokers’ (but not schizophrenics’) habit of carefully titrating
the nicotine dose generated by each cigarette.
In addition to alterations in reward, many nicotine-dependent
people display improved declarative memory for several minutes
to one hour after smoking (Myers et al., 2008). Because smokers
gradually learn toexploit this effect, it is called ‘‘cognitivesensitiza-
tion.’’ However, it is not known whether the nicotine-enhanced
cognitive performance exceeds the level that would occur if the
person had never begun to smoke, or after remaining abstinent
for one year (the usual criterion for successful smoking cessation)
(Levin et al., 2006). Cognitive sensitization probably involves fore-
brain-dependent processes (Xu et al., 2005; Davis and Gould,
2009; Kenny, 2011). In rodents and humans, the hippocampus is
importantly implicated in cognitive sensitization, and a4b2*
nAChRs play key roles (Levin et al., 2006; Davis and Gould,
2009). Chronic or acute nicotine enhances LTP in several regions
of hippocampus, especially dentate gyrus (Nashmi et al., 2007;
TangandDani, 2009;Pentonetal., 2011).Theeffectsmayproceed
via HS receptors on both the axons of the perforant path and the
intrinsic GABAergic interneurons (Gahring and Rogers, 2008).
Other nicotine-dependent people find that nicotine helps them
to cope with stressors; the soldier dangling a cigarette after
battle is an enduring image (Brandt, 2007). Relapse in response
to environmental or contextual stimuli such as stress—even after
months of abstinence—constitutes amajor challenge in smoking
cessation. Stress- and cue-induced reinstatement of nicotine
administration is studied far less frequently than analogous26 Neuron 70, April 14, 2011 ª2011 Elsevier Inc.phenomena for cocaine and opioids. The VTA-nucleus accum-
bens system does play a role. Several additional candidate brain
areas receive dopaminergic and other monoaminergic nerve
terminals, and these terminals all presumably express HS
nAChRs. For instance, dopamine increases in the extended
amygdala during stress, fear, and nicotine withdrawal (Inglis
and Moghaddam, 1999; Pape, 2005; Grace et al., 2007;
Gallagher et al., 2008; Koob, 2009; Marcinkiewcz et al., 2009).
We do not know whether either nAChR upregulation, or its
sequelae, can account for stress- or cue-induced relapse in
nicotine dependence.
nAChR Upregulation: The ‘‘Selectivity Hypothesis’’
and Its Functional Implications
Which molecular and cellular mechanisms could account for the
widespread actions of chronic nicotine on neuronal circuit prop-
erties? This puzzle does not yet have a complete answer, but it is
clear that chronic nicotine increases the number of nAChRs
themselves (Marks et al., 1983; Schwartz and Kellar, 1983). In
an emerging hypothesis, this ‘‘upregulation’’ is both necessary
and sufficient for the initial stages of nicotine exposure—
minutes, hours, days, and weeks. Remarkably, the upregulation
shows selectivity at every level thus far examined.
At the level of whole brain, chronic nicotine causes selective
upregulation of nAChRs among major brain regions. Upregula-
tion occurs in cortex, midbrain, and hypothalamus, but not in
thalamus or cerebellum (Pauly et al., 1991; Marks et al., 1992;
Nguyen et al., 2003; Nashmi et al., 2007; Doura et al., 2008). In
several brain regions, chronic nicotine administration produces
50%upregulation of HS nAChRs after just two days. Continued
administration then produces additional increases over one to
several weeks (Marks et al., 1991; Pietila¨ et al., 1998).
Within individual brain regions, there is selective upregulation
among cell types. In themidbrain, both DA neurons (in substantia
nigra pars compacta and ventral tegmental area [VTA]) and
GABAergic neurons (in substantia nigra pars reticulata and
VTA) express high levels of a4b2* nAChRs on their somata, but
only GABAergic neurons display somatic upregulation (Nashmi
et al., 2007; Xiao et al., 2009). Another example of cell-selective
upregulation occurs in the projection from medial entorhinal
cortex to dentate gyrus. In the medial perforant path, which
mainly arises from layer II stellate cells, chronic nicotine upregu-
lates a4b2* nAChRs. However in the temporoammonic pathway,
which mainly arises from layer III pyramidal neurons, a4b2*
nAChRs are present but are not upregulated (Nashmi et al.,
2007).
Chronic nicotine also produces selective upregulation
between somatodendritic versus axon terminal regions of indi-
vidual neurons. In midbrain, chronic nicotine treatment elicits
a general increase in a4b2* nAChRs in GABAergic neurons, but
only in axon terminals of DA neurons. Such ‘‘tiers of selectivity’’
in mesostriatal and mesolimbic upregulation have the power to
explain two components of nicotine dependence: tolerance to
some rewarding effects of nicotine and sensitization to others
(Nashmi et al., 2007; Lester et al., 2009).
Nicotine also interacts with specific nAChR subtypes, and
nicotine-induced upregulation is governed in part by these inter-
actions at agonist binding interfaces (Figure 1). Further work is
needed to understand how chronic nicotine differentially
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tivity in upregulation presumably arises because each neuronal
type expresses a distinct repertoire of subunits. GABAergic
neurons in DA brain regions express mostly a4b2 nAChRs along
with a few a4a5b2 nAChRs (McClure-Begley et al., 2009),
whereas DA neurons express at least three a4-containing
nAChRs (a4a6b2b3, a4a5b2, and a few a4b2) (Salminen et al.,
2004; Gotti et al., 2007). Although a6b3* nAChRs are, like a4b2
nAChRs, highly sensitive to nicotine, several studies demon-
strate that chronic nicotine treatment elicits either no change
or a decrease in a6b3* nAChRs in mouse brain (McCallum
et al., 2006a, 2006b; Mugnaini et al., 2006). Nicotine may also
subvert the coordinated regulation in place by other control
mechanisms, such as lynx proteins, through the preferential up-
regulation of one subtype resulting in imbalance in nicotinic
receptor signaling. It is too early, however, to conclude that
lynx proteins influence the effects of chronic nicotine exposure.
Emerging clues to selectivity at the subunit level, especially in
the context of nicotine dependence, concern the a5 subunit.
Figure 1 shows that this subunit never participates at the agonist
binding interface between a and b subunit but occupies a fifth
or ‘‘auxiliary’’ position. In rodent brain, most a5* nAChRs are
thought to be (a4)2(b2)2a5 pentamers (Gotti et al., 2006; Albu-
querque et al., 2009). In all known animals, the a5, a3, b4 genes
form a cluster. Indeed, (a3)2(b4)2a5 pentamers are widespread
in the peripheral nervous system, in the medial habenula, and
in some nonneuronal cell types. [We do not emphasize
(a3)2(b4)2a5 nAChRs or a3b4 nAChRs, because such nAChRs
have relatively low nicotine sensitivity and relatively low suscep-
tibility to upregulation.]
Single-nucleotide polymorphisms found in the human a5, a3,
b4 gene cluster are associated with nicotine dependence and
its age-dependent onset; number of cigarettes smoked per
day and ‘‘pleasurable buzz’’ elicited by smoking; alcoholism,
sensitivity to the depressant effects of alcohol, and age of
alcohol initiation; cocaine dependence; opioid dependence;
lung cancer; and cognitive flexibility (Erlich et al., 2010; Hansen
et al., 2010; Improgo et al., 2010; Saccone et al., 2010; Zhang
et al., 2010). A major ‘‘risk allele’’ is in a noncoding region of a5
and is associated with decreased expression of a5 subunit
mRNA (Wang et al., 2009). A second ‘‘risk allele’’ occurs in the
coding region, within the M3-M4 loop, and also produces
decreased function of (a4)2(b2)2a5 nAChRs (Wang et al., 2009;
Kuryatov et al., 2011). Furthermore in experiments using chronic
nicotine exposure in rats, (a4)2(b2)2a5 nAChRs are not upregu-
lated, but (presumptive) (a4)2(b2)3 nAChRs in the same brain
region are (Mao et al., 2008). Summarizing the available data,
the ‘‘risk alleles’’ may decrease the fraction of (a4)2(b2)2a5,
increasing that of a4b2 nAChRs. Because a4b2 nAChRs are
the most susceptible to nicotine-induced upregulation, the
data again seem consistent with the idea that selective upregu-
lation of a4b2 nAChRs underlies nicotine dependence. The
potential power of a4b2 upregulation to explain the initial events
of nicotine dependence thus derives from its selectivity, dis-
played at every level of organization: regional, neuronal, cellular,
and stoichiometric.
Selective upregulation would directly result in modified
neuronal excitability and neuronal interactions. As noted above,in the context of nicotine dependence, selective upregulation
presently has been studied in detail only in midbrain and in the
perforant path. Thus it remains an audacious hypothesis
that the initial stages of nicotine dependence can be explained
solely by ‘‘selective upregulation,’’ with no additional mecha-
nisms of regulation, adaptation, neuroadaptation, homeostasis,
or plasticity.
Despite the selectivity described above, upregulation also
displays an important generality. The upregulation of a4b2*
nAChRs by chronic nicotine treatment has been replicated
many times in numerous systems—transfected cell lines,
neurons in culture, brain slices, and smokers’ brains (Albuquer-
que et al., 2009; Fu et al., 2009; Lester et al., 2009; Srinivasan
et al., 2011). Upregulation is not accompanied by an increase in
nAChR subunit mRNA (Marks et al., 1992; Huang et al., 2007).
Instead, the membrane-permeant nicotine molecule appears
to act intracellularly, as a selective pharmacological chaperone
of acetylcholine receptor and stoichiometry (SePhaChARNS)
(Kuryatov et al., 2005; Sallette et al., 2005; Lester et al., 2009).
SePhaChARNS arises in part from the thermodynamics of phar-
macological chaperoning: ligand binding, especially at subunit
interfaces, stabilizes AChRs during assembly and maturation,
and this stabilization is most pronounced for the highest-affinity
nAChR subunit compositions (especially a4b2*), stoichiometries,
and functional states of nAChRs.
Upregulation Magnifies Both Activation
and Desensitization
Another general aspect of upregulation is its applicability to two
functional states induced by nicotine at nAChRs—activation and
desensitization (Figure 3). Smoked nicotine acts differently from
ACh in three ways (Lester et al., 2009). (1) Acetylcholinesterase
does not hydrolyze nicotine; therefore, nicotine remains near
nAChRs thousands of times longer than ACh. (2) Nicotine effi-
ciently permeates membranes; therefore, it accumulates within
cells (Putney and Borzelleca, 1971; Lester et al., 2009). (3)
Nicotine activates a4b2 nAChRs 400-fold more effectively
than it activates muscle-type nAChRs, because of cation-p
and H-bond interactions at the agonist binding site (Xiu et al.,
2009). These factors lead nicotine to activate and desensitize
the basal and nicotine-upregulated nAChRs for prolonged
periods (minutes to hours). Therefore, desensitization influences
actions of exogenous nicotine more than of endogenous ACh.
In summary, upregulation due to chronic nicotine can magnify
either activation or desensitization by acute nicotine. While it has
been debated whether the acute effects of nicotine arise from
activation or from desensitization, in the contemporary view
(Figure 3) (Picciotto et al., 2008) both are thought to occur at
appropriate neurons and synapses.
An Inadvertent Therapeutic Effect: Parkinson’s Disease
Neuroprotection
At first glance, nicotine addiction and Parkinson’s disease seem
related only by the participation of neighboring dopaminergic
neuron populations: the former involves dopamine release
from VTA neurons, and the latter involves degeneration in the
substantia nigra pars compacta. In fact, more than 50 studies
document an inverse correlation between a person’s history of
tobacco use and his/her risk of Parkinson’s disease (Ritz et al.,
2007). The effect is remarkably large—roughly a factor ofNeuron 70, April 14, 2011 ª2011 Elsevier Inc. 27
Figure 3. AGraphical View that Upregulation of nAChRsCanAmplify
Both the Effects of nAChR Activation and the Effects
of Desensitization
The vertical black arrow represents the level of nAChR activation at a synapse,
and the x axis represents the time course of activation and/or desensitization.
The cigarette represents an acute exposure to nicotine, in the context of either
nicotine-naive nAChRs (green) or nicotine-upregulated receptors (red).
(Top) Exposure to nicotine produces stronger activation at upregulated
receptors than at naive nAChRs, because upregulated nAChRs are both more
numerous and more sensitive.
(Bottom) A synapse where ongoing endogenous ACh mediates stronger
nAChR activation than at a naive synapse. Desensitization then produces
a correspondingly larger decrement of activity. The most common example of
such a desensitizing response to nicotine occurs at the presynaptic terminals
of nigrostriatal dopaminergic neurons (Xiao et al., 2009).
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epidemiological studies (Herna´n et al., 2002). Some Parkinson’s
disease cases (10%) are directly linked to genetic mutations.
However, when all genetic factors are eliminated by studying
monozygotic twins who are discordant for both tobacco use
and Parkinson’s disease, tobacco smoking and chewing still
decrease the risk of Parkinson’s disease (Tanner et al., 2002;
Wirdefeldt et al., 2005). Could selective upregulation contribute
to the apparent neuroprotective effects? We discuss three
possible mechanisms.
One mechanism may be via regulation of nAChR-containing
circuits (Nashmi et al., 2007; Xiao et al., 2009). While chronic
nicotine does not change the abundance or function of a4*
nAChRs in the somata of substantia nigra pars compacta dopa-
minergic neurons, it does suppress baseline firing rates of these
DA neurons. In mice exposed to chronic nicotine, GABA neurons
in substantia nigra pars reticulata have increased baseline firing
rates, both in brain slices and in anesthetized animals. These
contrasting effects on GABA and DA neurons are due to upregu-28 Neuron 70, April 14, 2011 ª2011 Elsevier Inc.lated a4* nAChR responses in GABA neurons, at both somata
and synaptic terminals. Thus chronic nicotine could regularize
the firing rates of substantia nigra DA neurons, preventing
them from experiencing bursts that could lead to excitotoxic
Ca2+ influx.
Another neuroprotective mechanism may occur at nerve
terminals in the striatum. Chronic nicotine upregulates a4*
nAChRs in dopaminergic presynaptic terminals, apparently
leading to increased resting dopamine release from those termi-
nals. This effect produces a basal decrease in the level of gluta-
mate release from corticostriatal neurons (Xiao et al., 2009). The
process may counteract the increased effectiveness of cortico-
striatal glutamatergic inputs during degeneration of the DA
system.
A third neuroprotective mechanism may operate entirely
within DA neurons. The chaperoning of nAChRs by nicotine
enhances the export of a4b2 nAChRs from the endoplasmic
reticulum (ER), and this leads to a general increase in ER exit
sites (Srinivasan et al., 2011). This aspect of SePhaChARNS
eventually leads to plasma membrane upregulation. We hypoth-
esize that, in addition, this process lowers the demands on the
general proteostatic machinery in the ER, thereby altering ER
stress, which is frequently invoked as a toxic mechanism in
Parkinson’s disease.
A Second Inadvertent Therapeutic Effect: ADNFLE
Autosomal-dominant nocturnal frontal lobe epilepsy (ADNFLE) is
caused by missense mutations in either the a4 or the b2 subunit.
Several strains of knock-in mice bearing these mutations have
seizure phenotypes related to ADNFLE (Klaassen et al., 2006;
Teper et al., 2007; Xu et al., 2010), but a4 KO and b2 KO mice
display no seizure phenotypes, implying that ADNFLE has
a subtle, as yet unexplained pathophysiology. ADNFLE patients
who use a nicotine patch or tobacco have fewer seizures
(Willoughby et al., 2003; Brodtkorb and Picard, 2006). Recent
data suggest that ADNFLE mutations bias nAChR composition
away from the (a4)2(b2)3 stoichiometry, which is then re-estab-
lished by nicotine exposure (Son et al., 2009). Thus, changes in
a4b2* nAChR stoichiometry, subunit composition, and sorting
could contribute both to the etiology of ADNFLE and to the
inadvertent therapeutic effects of nicotine. This highly penetrant
monogenic disease could eventually provide important clues to
the pathophysiology and therapy of complex polygenic diseases
such as Parkinson’s disease and nicotine dependence.
Thus, chaperoning of nascent nAChRs by smoking-relevant
concentrations of nicotine represents a form of nicotine-nAChR
interaction that is not directly associated with ion flux through
active nAChRs. Chaperoning may provide a partial explanation
for the pathological process of nicotine addiction and also for
the inadvertent therapeutic effects of tobacco use in Parkinson’s
disease and ADNFLE. Some effects of chaperoning may actually
occur at the level of nAChR stabilization in the endoplasmic retic-
ulum, and others arise from the consequent upregulation at the
plasma membrane.
Conclusions
The Introduction posed the problem of explaining how manipu-
lations of nicotinic synapses, which have been considered
all-or-none machines, can produce the graded modulation of
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(admittedly partial) explanations. First, recent evidence supports
the graded ‘‘volume transmission’’ hypothesis (Ren et al., 2011).
Second, the prototoxin lynx can function, probably both intracel-
lularly and extracellularly, to direct the localization and activity of
nAChRs. Absence of lynx has the profound modulatory effect of
lengthening the critical period for ocular dominance plasticity.
Third, a7 nAChRs can be activated in extrasynaptic regions by
ambient concentrations of choline, with possible consequences
for neuronal development as well as for circuit function during
schizophrenia. Finally, the pharmacokinetics and stability of
nicotine allow it to influence nAChRs in environments not
reached by acetylcholine itself—extracellularly on somata, and
intracellularly in the ER, where nicotine functions as a pharmaco-
logical chaperone to upregulate certain HS receptors. Further-
more, nicotine’s persistence leads to desensitization of nAChRs.
For more than four centuries, nicotinic systems have unfortu-
nately played a role in drug abuse, but we have reviewed ways
in which nicotinic systems can also be manipulated to provide
help for neural illnesses such as Parkinson’s disease, cognitive
decline, epilepsy, and schizophrenia. Nicotinic systems will
continue to serve as touchstones for advances in neuroscience.ACKNOWLEDGMENTS
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